Masivet® information for veterinarians
Masivet® is intended for the treatment of inoperable mast cell tumors in dogs (grade 2 or 3) or as post-treatment after (partial) removal of the tumor. The drug is a tyrosine kinase inhibitor and similar to Palladia®. Masivet® acts on the KIT receptor. This tyrosine kinase receptor regulates the growth or cell division of certain cells. In 15-40% of mast cell tumors, the cancer arises because there is damage to the KIT receptor. The receptor is on "on" all the time, and therefore the cells keep growing and dividing. Masivet® turns the KIT receptor "off" again. Administration is via 50 mg or 150 mg tablets. The tablets should not be broken.
Please contact Maxani by phone if you are a veterinarian wishing to order Masivet® for the first time or would like more information about Masivet®. If you want to place a repeat order please log into the webshop. For pet owners this product is only available through the veterinarian. More information about Masivet® can be found below.
Masivet® is shipped and billed from AB Science in France. Delivery time is therefore 4 to 5 working days. One jar of Masivet® contains 30 tablets.
- 50 mg Masivet®, registration number: 100191
- 150 mg Masivet®, registration number: 100198
How does Masivet® work?
Masivet® contains the active ingredient masitinib. Masitinib is a Protein Tyrosine Kinase (PTK) inhibitor to treat mast cell tumors that acts on c-KIT. C-KIT is a receptor for mast cell growth factor and is found in the cell wall. C-KIT is found in all humans and animals and plays an important role in the normal physiology of the cell. C-KIT plays a role in communication, development, division and growth of cells through phosphorylation of proteins. It functions as a kind of on/off switch for these cell functions. Mutations in the c-KIT gene are found in 20% of mast cell tumors in dogs. C-KIT is a proto/oncogene, which when mutated can cause increased proliferation. Another cause of mast cell tumors is that the c-KIT is continuously "on" without signaling by binding mast cell growth factor. This c-KIT seems 'addicted to ATP' and thus continues to phosphorylate proteins and transmit signals to growth and division in the cell. Thus, in most cases, a c-KIT test does not reveal whether or not treatment with Masivet® is successful, as it looks for a gene mutation that is the cause in only 20% of mast cell tumors.